This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024. CI
Certain Warrants of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024. CI
Certain Stock Options of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024. CI
B. Riley Raises Price Target on Perspective Therapeutics to $1.70 From $1.20, Maintains Buy Rating MT
Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.50 From $1.20, Maintains Outperform Rating MT
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Markets Steady -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study MT
Transcript : Perspective Therapeutics, Inc. - Analyst/Investor Day
Perspective Therapeutics, Inc. Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb)VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma CI
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. and other investors CI
Sector Update: Health Care Stocks Softer in Afternoon Trading MT
Perspective Therapeutics to Raise $87.4 Million in Private Placement MT
Perspective Therapeutics, Inc. completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc. CI
Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform CI
B. Riley Starts Perspective Therapeutics With Buy Rating, $1.20 Price Target; Says Well-Positioned to Break Out of Biotech Pack MT
Perspective Therapeutics Closes $89.8 Million Public Offering, Concurrent Private Placement MT
Perspective Therapeutics to Raise Nearly $81 Million via Public Offering, Private Placement MT
Sector Update: Health Care Stocks Mixed Premarket Thursday MT
Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding CI
Perspective Therapeutics Launching Public Offering MT
Perspective Therapeutics, Inc. Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs CI
Lantheus Holdings Signs Share Purchase, Licensing Deals With Perspective Therapeutics MT
Perspective Therapeutics, Inc. Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability CI
Chart Perspective Therapeutics, Inc.
More charts
Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Company’s core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Company’s segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.58 USD
Average target price
1.6 USD
Spread / Average Target
+1.27%
Consensus
  1. Stock Market
  2. Equities
  3. CATX Stock
  4. News Perspective Therapeutics, Inc.
  5. Perspective Therapeutics to Raise $87.4 Million in Private Placement